Results 81 to 90 of about 12,104 (196)

Use of Tissue-Specific MicroRNA to Control Pathology of Wild-Type Adenovirus without Attenuation of Its Ability to Kill Cancer Cells [PDF]

, 2009
Replicating viruses have broad applications in biomedicine, notably in cancer virotherapy and in the design of attenuated vaccines; however, uncontrolled virus replication in vulnerable tissues can give pathology and often restricts the use of potent ...
Ryan Cawood, Hannah H. Chen, Fionnadh Carroll, Miriam Bazan-Peregrino, Nico van Rooijen, Leonard W. Seymour, Klaus Früh, TC Liu, RM Zinkernagel, M Vignuzzi, D Kirn, EJ Small, M Lagos-Quintana, S Deng, RS Pillai, TW Nilsen, M Lagos-Quintana, BD Brown, BD Brown, D Barnes, EJ Kelly, J Chang, SJ Duncan, SM Frisch, M Bazan-Peregrino, E Ylosmaki, N Mittereder, G Karber, NK Green, N Van Rooijen   +29 more
core   +3 more sources

Activation of Nrf2 signaling augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity [PDF]

, 2017
Oncolytic viruses (OVs) offer a promising therapeutic approach to treat multiple types of cancer. In this study, we show that the manipulation of the anti-oxidant network via transcription factor Nrf2 augments vesicular stomatitis virus Δ51 (VSVΔ51 ...
David Olagnier, Rassin R. Lababidi, Samar Bel Hadj, Alexandre Sze, Yiliu Liu, Sharadha Dayalan Naidu, Matteo Ferrari, Yuan Jiang, Cindy Chiang, Vladimir Beljanski, Marie-Line Goulet, Elena V. Knatko, Albena T. Dinkova-Kostova, John Hiscott, Rongtuan Lin, Ilkow, Breitbach, Swift, Lichty, Rehman, Russell, Altomonte, Arulanandam, Ben Yebdri, Nguyên, Ottolino-Perry, Shulak, Dobson, Marchini, Breitbach, Rowan, Stojdl, Stojdl, Samuel, Nguyen, Baird, Jaramillo, Greaney, Qi, Traka, Alumkal, Cipolla, van Die, Furfaro, Jeong, Singh, Lee, Lee, Dinkova-Kostova, Biswas, Herman-Antosiewicz, Jounai, Pajares, Hiscott, Zhang, Fahey, Lenzi, Dinkova-Kostova, Singh, Hu, Zhang, McMahon, Alexander, Otterbein, Alain, Yang, Liu, Simpson, Rajani, Bridle, Bridle, Lemay, Kallifatidis, Erzinger, Higgins, Wakabayashi, Kovac, Kuma, Olagnier, Chiang, Olagnier, Belgnaoui, Zhao, Ivanov, Massrieh, Song   +85 more
core   +4 more sources

Oncolytic viruses: how “lytic” must they be for therapeutic efficacy?

OncoImmunology, 2019
Oncolytic viruses (OVs) preferentially target and kill cancer cells without affecting healthy cells through a multi-modal mechanism of action. While historically the direct killing activity of OVs was considered the primary mode of action, initiation or ...
Maria Eugenia Davola, Karen Louise Mossman   +1 more
doaj   +1 more source

Virotheranostics, a double-barreled viral gun pointed toward cancer; ready to shoot?

Cancer Cell International, 2020
Compared with conventional cancer treatments, the main advantage of oncolytic virotherapy is its tumor-selective replication followed by the destruction of malignant cells without damaging healthy cells.
Mohsen Keshavarz, Ailar Sabbaghi, Seyed Mohammad Miri, Abolhasan Rezaeyan, Yaser Arjeini, Amir Ghaemi   +5 more
doaj   +1 more source

Literature review: Virus and cancer [PDF]

, 2017
Traballo fin de grao (UDC.CIE). Bioloxía. Curso 2016/2017[Abstract] Cancer is one of the main causes of global mortality, and even though it is considered to be a non-communicable disease, several infectious agents have been found to contribute to ...
Carreira Santos, Sofía
core  

Tumour-associated macrophages and oncolytic virotherapies:a mathematical investigation into a complex dynamics [PDF]

, 2018
Anti-cancer therapies based on oncolytic viruses are emerging as important approaches in cancer treatment. However, the effectiveness of these therapies depends significantly on the interactions between the oncolytic viruses and the host immune response.
Bridle B. W., Kaufman H. L., Looney W., Makitie T., Nowak M., Sang Y., Wodarz D.   +6 more
core   +3 more sources

Tumor dynamics model with treatments by oncolytic virotherapy and MEK inhibitors involving TNF-α inhibitors: Stability analysis and optimal control

Computational and Mathematical Biophysics
Oncolytic virotherapy is one of the cancer treatments that kills cancer cells but leaves normal cells. Furthermore, mitogen-activated protein kinase (MEK) inhibitors boost chimeric antigen receptor expression and increase oncolytic virus entry into tumor
Daengkongkho Salinthip, Viriyapong Ratchada   +1 more
doaj   +1 more source

Oncolytic Viruses Partner With T-Cell Therapy for Solid Tumor Treatment

Frontiers in Immunology, 2018
Adoptive T-cell immunotherapies, including chimeric antigen receptor-modified T-cells (CAR-T cells), have revolutionized cancer treatment, especially for hematologic malignancies.
Amanda Rosewell Shaw, Amanda Rosewell Shaw, Masataka Suzuki, Masataka Suzuki   +3 more
doaj   +1 more source

Oncolytic Adenovirus-Induced Autophagy: Tumor-Suppressive Effect and Molecular Basis [PDF]

, 2013
Autophagy is a catabolic process that produces energy through lysosomal degradation of intracellular organelles. Autophagy functions as a cytoprotective factor under physiological conditions such as nutrient deprivation, hypoxia, and interruption of ...
Fujiwara, Toshiyoshi, Kagawa, Shunsuke, Tazawa, Hiroshi   +2 more
core   +1 more source

Myelolytic Treatments Enhance Oncolytic Herpes Virotherapy in Models of Ewing Sarcoma by Modulating the Immune Microenvironment

Molecular Therapy: Oncolytics, 2018
Ewing sarcoma is a highly aggressive cancer that promotes the infiltration and activation of pro-tumor M2-like macrophages. Oncolytic virotherapy that selectively infects and destroys cancer cells is a promising option for treating Ewing sarcoma.
Nicholas L. Denton, Chun-Yu Chen, Brian Hutzen, Mark A. Currier, Thomas Scott, Brooke Nartker, Jennifer L. Leddon, Pin-Yi Wang, Rachelle Srinivas, Kevin A. Cassady, William F. Goins, Timothy P. Cripe   +11 more
doaj   +1 more source